Last reviewed · How we verify
Diclofenac Sodium Active Topical Patch 2 — Competitive Intelligence Brief
phase 2
NSAID
COX-2
Pain Management
Small molecule
Live · refreshed every 30 min
Target snapshot
Diclofenac Sodium Active Topical Patch 2 (Diclofenac Sodium Active Topical Patch 2) — Noven Pharmaceuticals, Inc.. Diclofenac Sodium is a non-selective COX-2 inhibitor.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Diclofenac Sodium Active Topical Patch 2 TARGET | Diclofenac Sodium Active Topical Patch 2 | Noven Pharmaceuticals, Inc. | phase 2 | NSAID | COX-2 | |
| Celebrex | celecoxib | Pfizer Inc. (originally Searle/Pharmacia) | marketed | Nonsteroidal Anti-inflammatory Drug [EPC] | COX-2 | 1998-12-31 |
| Cytotec | Misoprostol | Pfizer | marketed | NSAID combined with prostaglandin analog | Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors | 1988-01-01 |
| Ibuprofen/acetaminophen | Ibuprofen/acetaminophen | Montefiore Medical Center | marketed | Analgesic/antipyretic combination (NSAID + non-NSAID analgesic) | Cyclooxygenase (COX-1, COX-2) for ibuprofen; prostaglandin synthesis and central pain pathways for acetaminophen | |
| Ibuprofen suppository | Ibuprofen suppository | Assaf-Harofeh Medical Center | marketed | Nonsteroidal anti-inflammatory drug (NSAID) | Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) | |
| Naproxen Sodium Codeine | Naproxen Sodium Codeine | Istanbul Medeniyet University | marketed | NSAID + opioid combination analgesic | COX-1/COX-2 enzymes; mu opioid receptor | |
| Dexketoprofen Trometamol + Thiocolchicoside | Dexketoprofen Trometamol + Thiocolchicoside | Yuzuncu Yil University | marketed | NSAID + muscle relaxant combination | COX-1/COX-2 (dexketoprofen); GABA receptors and microtubule dynamics (thiocolchicoside) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Celebrex · 10722456 · Formulation · US
- — Celebrex · 10799517 · Formulation · US
- — Celebrex · 9949990 · Formulation · US
- — Celebrex · 9795620 · Formulation · US
- — Celebrex · 9572819 · Formulation · US
- — Celebrex · 10376527 · Formulation · US
Sponsor landscape (NSAID class)
- Antibe Therapeutics Inc. · 3 drugs in this class
- Iroko Pharmaceuticals, LLC · 3 drugs in this class
- Organon and Co · 2 drugs in this class
- Apsen Farmaceutica S.A. · 2 drugs in this class
- Amneal Pharmaceuticals, LLC · 2 drugs in this class
- Behar, Caren, M.D. · 2 drugs in this class
- IDEA AG · 2 drugs in this class
- Noven Pharmaceuticals, Inc. · 2 drugs in this class
- HALEON · 2 drugs in this class
- Pfizer · 2 drugs in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Diclofenac Sodium Active Topical Patch 2 CI watch — RSS
- Diclofenac Sodium Active Topical Patch 2 CI watch — Atom
- Diclofenac Sodium Active Topical Patch 2 CI watch — JSON
- Diclofenac Sodium Active Topical Patch 2 alone — RSS
- Whole NSAID class — RSS
Cite this brief
Drug Landscape (2026). Diclofenac Sodium Active Topical Patch 2 — Competitive Intelligence Brief. https://druglandscape.com/ci/diclofenac-sodium-active-topical-patch-2. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing